By Tony Fong

NEW YORK (GenomeWeb News) – By now, most life science tool companies have reported their earnings results for the most recently completed quarter. As many of the firms covered by GenomeWeb Daily News reported jumps in revenues year over year, with some improving substantially, many singled out the performance of technologies such as next-generation sequencers, mass spectrometers, and PCR systems not only as revenue drivers for the quarter just ended but also for the future.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.